Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colombe Chappey

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
AIDS (London, England)|March 12, 2009
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaSusan H Eshleman, Oliver Laeyendecker, Neil Parkin, et al.
Journal of Virology|November 16, 2004
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesJames M Binley, Terri Wrin, Bette Korber, et al.
Plos Computational Biology|December 4, 2009
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1Sergei L Kosakovsky Pond, David Posada, Eric Stawiski, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 14, 2009
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt, Jeff Sperinde, Fanny Piette, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2005
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionSimon D W Frost, Terri Wrin, Davey M Smith, et al.
The Journal of Experimental Medicine|March 15, 2006
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusRika Draenert, Todd M Allen, Yang Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)Nicholas C Turner, Melinda L Telli, Hope S Rugo, et al.
Clinical Trials (London, England)|March 4, 2026
Leveraging generative AI to transform statistical analysis plan authoring in clinical trialsRogier Landman, Birol Emir, Richard Zhang, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Plos Medicine|January 18, 2007
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanismMonique Nijhuis, Noortje M van Maarseveen, Stephane Lastere, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
AIDS (London, England)|March 12, 2009
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaSusan H Eshleman, Oliver Laeyendecker, Neil Parkin, et al.
Journal of Virology|November 16, 2004
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesJames M Binley, Terri Wrin, Bette Korber, et al.
Plos Computational Biology|December 4, 2009
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1Sergei L Kosakovsky Pond, David Posada, Eric Stawiski, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 14, 2009
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt, Jeff Sperinde, Fanny Piette, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2005
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionSimon D W Frost, Terri Wrin, Davey M Smith, et al.
The Journal of Experimental Medicine|March 15, 2006
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusRika Draenert, Todd M Allen, Yang Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)Nicholas C Turner, Melinda L Telli, Hope S Rugo, et al.
Clinical Trials (London, England)|March 4, 2026
Leveraging generative AI to transform statistical analysis plan authoring in clinical trialsRogier Landman, Birol Emir, Richard Zhang, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Plos Medicine|January 18, 2007
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanismMonique Nijhuis, Noortje M van Maarseveen, Stephane Lastere, et al.
Pageof 4